Krystal Biotech Unit Launches VYJUVEK In Japan For Treatment Of Dystrophic Epidermolysis Bullosa; VYJUVEK Priced At ¥2,955,232.7 Per Unit In Japan

Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK® (beremagene geperpavec) in Japan for the treatment of dystrophic epidermolysis bullosa following its inclusion on Japan's National Health Insurance (NHI) Drug Price Liston the same date. VYJUVEK has been listed on the NHI Drug Price List at a price of 2,955,232.7 yen per unit. This Current Report on Form 8-K is being furnished for informational purposes only.